Evidence map›Paper›PMID 32566564›Full record

ArticleAnnals of translational medicine2020

Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.

Shuya Lu, Qi Zhou, Liping Huang, Qianling Shi, Siya Zhao, Zijun Wang, Weiguo Li, Yuyi Tang, Yanfang Ma, Xufei Luo and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 7 pooled it
1.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 7 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Shuya LuDepartment of Pediatric, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
Qi ZhouEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Liping HuangDepartment of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Qianling ShiEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Siya ZhaoSchool of Public Health, Lanzhou University, Lanzhou 730000, China.
Zijun WangEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Weiguo LiDepartment of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Yuyi TangDepartment of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Yanfang MaEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Xufei LuoEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Toshio FukuokaEmergency and Critical Care Center, the Department of General Medicine, Department of Research and Medical Education at Kurashiki Central Hospital, Kurashiki, Japan.
Hyeong Sik AhnDepartment of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
Myeong Soo LeeKorea Institute of Oriental Medicine, Daejeon, Korea.
Zhengxiu LuoDepartment of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Enmei LiuDepartment of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Yaolong ChenEvidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Chenyan ZhouDepartment of Pediatric, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
Donghong PengDepartment of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
China International Science and Technology Cooperation · CNUniversity of Electronic Science and Technology of China · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucocorticoids are widely used in the treatment of various pulmonary inflammatory diseases, but they are also often accompanied by significant adverse reactions. Published guidelines point out that low dose and short duration systemic glucocorticoid therapy may be considered for patients with rapidly progressing coronavirus disease 2019 (COVID-19) while the evidence is still limited.

methodsWe comprehensively searched electronic databases and supplemented the screening by conducting a manual search. We included randomized controlled trials (RCTs) and cohort studies evaluating the effectiveness and safety of glucocorticoids in children and adults with COVID-19, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and conducted meta-analyses of the main indicators that were identified in the studies.

resultsOur search retrieved 23 studies, including one RCT and 22 cohort studies, with a total of 13,815 patients. In adults with COVID-19, the use of systemic glucocorticoid did not reduce mortality [risk ratio (RR) =2.00, 95% confidence interval (CI): 0.69 to 5.75, I

conclusionsGlucocorticoid therapy was found to reduce the duration of fever, but not mortality, duration of hospitalization or lung inflammation absorption. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as coinfections, so routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommend.

Indexed as

Coronavirus disease 2019 (COVID-19)glucocorticoidsmeta-analysisrapid review

Identifiers

PMID32566564
PMCPMC7290628
OpenAlexW3027130964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.